Durable response to pralatrexate for aggressive PTCL subtypes

被引：0
|
作者：
Farhan, Ahmed [1 ]
Strelec, Lauren E. [1 ]
Schuster, Stephen J. [1 ]
Torigian, Drew [1 ]
Wasik, Mariusz [1 ]
Sadigh, Sam [1 ]
Mato, Anthony R. [1 ]
Nasta, Sunita Dwivedy [1 ]
Frank, Dale [1 ]
Svoboda, Jakub [1 ]
机构：
[1] Univ Penn, Abrahamson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2018年 / 16卷 / 02期
关键词：
D O I：
10.12788/jcso.0369
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E102 / E105
页数：4
相关论文
共 50 条
  • [1] Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival
    Shustov, A. R.
    Pro, B.
    Horwitz, S. M.
    Jacobsen, E. D.
    Boyd, A.
    Fruchtman, S. M.
    O'Connor, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Pralatrexate, a new hope for aggressive T-cell lymphomas?
    Rueda, Antonio
    Casanova, Maria
    Quero, Cristina
    Medina-Perez, Angeles
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (04): : 215 - 220
  • [3] Pralatrexate, a new hope for aggressive T-cell lymphomas?
    Antonio Rueda
    María Casanova
    Cristina Quero
    Ángeles Medina-Pérez
    Clinical and Translational Oncology, 2009, 11 : 215 - 220
  • [4] Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).
    Pettengell, Ruth
    Coiffier, Bertrand
    Narayanan, Geetha
    Hurtado de Mendoza, Fernando
    Digumarti, Raghunadharao
    Gomez, Henry
    Zinzani, Pier Luigi
    Schiller, Gary J.
    Rizzieri, David A.
    Cernohous, Paul
    Wang, Lixia
    Singer, Jack W.
    BLOOD, 2009, 114 (22) : 669 - 669
  • [5] Pralatrexate (PDX) produces a high and durable complete response rate in patients with chemotherapy resistant T-cell lymphomas
    O'Connor, O. A.
    Hamlin, P.
    Moskowitz, C.
    Portlock, C.
    Sarasohn, D.
    Dumitrescu, O.
    Neylon, E.
    Patterson, M.
    Zelenetz, A.
    Saunders, M.
    Cagnoni, P.
    Mould, D.
    Fleisher, M.
    Califano, A.
    Sirotnak, F.
    Horwitz, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [6] Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)
    Moskowitz, Alison J.
    Stuver, Robert N.
    Horwitz, Steven M.
    BLOOD, 2024, 144 (18) : 1887 - 1897
  • [7] PRALATREXATE ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL): RELATIONSHIP BETWEEN RESPONSE AT CYCLE 1 AND SUBSEQUENT SURVIVAL
    Coiffier, B.
    Zinzani, P. L.
    Gisselbrecht, C.
    Shustov, A.
    Pro, B.
    Horwitz, S.
    Jacobsen, E.
    Koutsoukos, T.
    Fruchtman, S.
    O'Connor, O.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 122 - 122
  • [8] Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind
    Altinay, Serdar
    Kural, Alev
    Ozmen, Aykut
    Tural, Deniz
    Tutar, Yusuf
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (03) : 298 - 305
  • [9] Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).
    Pinter-Brown, Lauren
    Horwitz, Steven M.
    Pro, Barbara
    Zinzani, Pier Luigi
    Gisselbrecht, Christian
    Cortelli, Barbara MacGregor
    Fruchtman, Steven
    O'Connor, Owen A.
    BLOOD, 2009, 114 (22) : 668 - 668
  • [10] Predicting the responder for pralatrexate against PTCL: a post hoc analysis of PDX-JP1 study
    Shimazu, Y.
    Kitawaki, T.
    Tonai, T.
    Floris, D.
    Takaori-Kondo, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1324 - S1324
12345